Skip to main content
BC Innovations
Feature Story

Making sense of sensors

Targeting nucleic acid sensors makes sense for cancer

By Michael Leviten, Senior Writer

Two new pathways are emerging as viable options for harnessing nucleic acid sensors in immuno-oncology, offering an alternative to the toll-like receptors (TLRs) that paved the way. By activating STING or RIG-I, researchers are expanding the possibilities for tapping into the innate immune system to create stand-alone treatments or combination therapies with checkpoint inhibitors.

With one compound targeting STING in Phase I and another targeting RIG-I scheduled to enter the clinic in 2017, companies are looking at the pathways as sources of new targets that could help establish or boost their immuno-oncology portfolios.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial